Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults

Journal of Clinical Psychiatry

Volumn 75, Issue 8, 2014, Pages e785-e793

  Karp, Jordan F ^a   Butters, Meryl A ^b   Begley, Amy E ^b   Miller, Mark D ^b   Lenze, Eric J ^d   Blumberger, Daniel M ^e   Mulsant, Benoit H ^b,e   Reynolds, Charles F ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; LORAZEPAM; VENLAFAXINE; NARCOTIC ANTAGONIST;

ADULT; ADVERSE DRUG REACTION; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING DISORDER; LOW DRUG DOSE; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SLEEP PARAMETERS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VITAL SIGN; WEIGHT GAIN; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; COGNITION; DOSE RESPONSE; ONSET AGE; SLEEP; TREATMENT OUTCOME;

AGE OF ONSET; AGED; BUPRENORPHINE; COGNITION; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; QUALITY OF LIFE; SLEEP; TREATMENT OUTCOME;

EID: 84908351930     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13m08725     Document Type: Article

References (47)

1. Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry. 2007;164(6):892-899.
2. Rush AJ, Trivedi M, Fava M. Depression, IV: STARD treatment trial for depression. Am J Psychiatry. 2003;160(2):237.
3. Thase M, Rush A. Treatment resistant depression. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Lippincott, Williams, and Wilkins; 1995.
4. Tao R, Auerbach SB. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther. 2002;303(2):549-556.
5. Hache G, Coudore F, Gardier A, et al. Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of triple reuptake inhibitors (TRIs). Pharmaceuticals (Ott). 2011;4(12):285-342.
6. Fink M, Simeon J, Itil TM, et al. Clinical antidepressant activity of cyclazocine-A narcotic antagonist. Clin Pharmacol Ther. 1970;11(1):41-48.
7. Gerner RH, Catlin DH, Gorelick DA, et al. Beta-endorphin: intravenous infusion causes behavioral change in psychiatric inpatients. Arch Gen Psychiatry. 1980;37(6):642-647.
8. Ruther E, Jungkunz G, Nedopil N. Clinical effects of the synthetic analogue of methionine enkephalin FK 33-824. Presented at: 3rd World Congress of Biological Psychiatry; June 28-July 3, 1981; Stockholm, Sweden.
9. Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49-65.
10. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003;305(1):323-330.
11. Sbrenna S, Marti M, Morari M, et al. Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol. 2000;130(2):425-433.
12. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49-57.
13. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7(1):51-54.
14. Butters MA, Whyte EM, Nebes RD, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61(6):587-595.
15. Soyka M, Lieb M, Kagerer S, et al. Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial. J Clin Psychopharmacol. 2008;28(6):699-703.
16. Dagtekin O, Gerbershagen HJ, Wagner W, et al. Assessing cognitive and psychomotor performance under long-Term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth Analg. 2007;105(5):1442-1448.
17. Blier P, Saint-Andre E, Hebert C, et al. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007;10(1):41-50.
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
19. Oquendo MA, Baca-Garcia E, Kartachov A, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry. 2003;64(7):825-833.
20. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSMIV Axis I Disorders (SCID). Washington, DC: American Psychiatric Press; 1997.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
22. Mulsant B, Sweet R, Rifai A, et al. The use of the Hamilton Rating Scale for Depression in elderly patients with cognitive impairment and physical illness. Am J Geriatr Psychiatry. 1994;2(3):220-229.
23. Williams J, Kobak K, eds. Improving inter-rater reliability in clinical trials: development and validation of a Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). Presented at: International Society for CNS Clinical Trials and Methodology 3rd Annual Scientific Congress; 2007; Washington, DC.
24. Derogatis L. Brief Symptom Inventory (BSI): Administration, Scoring, and Procedures Manual. 3rd ed. Minneapolis, MN: National Computer Systems; 1993.
25. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190(4):344-349.
26. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. J Pers Soc Psychol. 1988;54(6):1063-1070.
27. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: The Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343-352.
28. Beck AT, Brown GK, Steer RA, et al. Suicide ideation at its worst point: A predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav. 1999;29(1):1-9.
29. Beck AT, Brown GK, Steer RA. Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients. Behav Res Ther. 1997;35(11):1039-1046.
30. Rapeli P, Fabritius C, Kalska H, et al. Cognitive functioning in opioiddependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol. 2011;11(1):13.
31. Jennings JR, Mendelson DN, Redfern MS, et al. Detecting age differences in resistance to perceptual and motor interference. Exp Aging Res. 2011;37(2):179-197.
32. Shapiro AM, Benedict RH, Schretlen D, et al. Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised. Clin Neuropsychol. 1999;13(3):348-358.
33. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-Treated patients. Acta Psychiatr Scand Suppl. 1987;76(s334):1-100.
34. Wisniewski SR, Rush AJ, Balasubramani GK, et al; TARD Investigators. Selfrated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-79.
35. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14(9):796-802.
36. Ware J, Gandek B, the IQOLA project group. The SF-36 Health Survey: development and use in mental health research and IQOLA project. Int J Ment Health. 1994;23(2):49-73.
37. Dombrovski AY, Lenze EJ, Dew MA, et al. Maintenance treatment for old-Age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc. 2007;55(9):1325-1332.
38. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
39. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-259.
40. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-909.
41. Chapman SL, Byas-Smith MG, Reed BA. Effects of intermediate- And longterm use of opioids on cognition in patients with chronic pain. Clin J Pain. 2002;18(suppl):S83-S90.
42. Golwyn DH, Sevlie CP. Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension. J Clin Psychopharmacol. 1993;13(1):77-78.
43. Tulen JHM, Volkers AC, van den Broek WW, et al. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressantrefractory depression. J Clin Psychopharmacol. 2006;26(5):542-544.
44. Kivimaki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: A population-based study. Diabetes Care. 2010;33(12):2611-2616.
45. Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: A pooled analysis of placebo-controlled studies. Drug Saf. 2010;33(5):393-407.
46. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
47. Schatzberg AF, Haddad P, Kaplan EM, et al; Discontinuation Consensus Panel. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry. 1997;58(suppl 7):5-10.